Investing

Boston Scientific: The Company That Never Turned Around

Dollar Yen ParityBoston Scientific Corp. (NYSE: BSX) may have been the premier medical supply company in the world — in 2006, before it bought rival Guidant, then had a series of problems with its stents and other widely used devices. There is an illusion that the company has turned around, but it is nothing more than that.

Boston Scientific’s share price has almost doubled since October to just above $7.50 The activity seems impressive, unless it is viewed in light of the stock’s longer term performance. Shares are down 40% over the past five years, while the S&P is higher by more than 10%. That makes the stock among the worst performing among large companies over those five years.

Easily forgotten in light of the market’s recent enthusiasm about the company is that it has lost money six of the past seven years. Boston Scientific’s revenue peaked in 2007 at $8.4 billion. Last year, the comparable number was $7.2 billion. In 2012, Boston Scientific lost more than $4 billion, much of it due to special charges.

Wall St. still does not expect much from the company in the next year, another reason the run up in the stock is odd. According to analysts from Morningstar:

In terms of its pipeline, we think Boston has fallen behind its key competitors in the race to develop and introduce the emerging technologies that are likely to fuel growth in cardiac devices over the next decade.

Analysts expect 2013 revenue to drop by 2% to $7.2 billion. So, Boston Scientific will not post any breakthroughs in its business that will transform it to a level at which it could be viewed as successful.

Short-term trends in share prices often mask a historic string of failures, as well as beg investors to consider how companies have been run and have performed long term. If there is any case to be made for that kind of examination, it is Boston Scientific, which has done nothing for shareholders in eight years.

Take Charge of Your Retirement In Just A Few Minutes (Sponsor)

Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s simple quiz makes it easier than ever for you to connect with a vetted financial advisor.

Here’s how it works:

  1. Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
  2. Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
  3. Choose Your  Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.

Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!

 

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.

AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.